Literature DB >> 7548871

[Magnetic resonance tomography and localized proton spectroscopy in 2 siblings with Canavan's disease].

V Engelbrecht1, M Rassek, J Gärtner, T Kahn, U Mödder.   

Abstract

We present the findings of magnetic resonance imaging (MRI) and localised 1H magnetic resonance spectroscopy (MRS) in two brothers with Canavan's disease, a rare autosomal recessive leukodystrophy. Urine specimens of one child were evaluated by MRS. All examinations were performed in the same whole body 1.5 T superconducting magnet. MRI revealed the typical pattern of leukodystrophy including a more severe demyelination in the older child. The younger brother showed additional high signal lesions in the globi pallidi on T2-weighted images. MRS of the brain had an elevated ratio of N-acetyl-aspartate (NAA)/phosphocreatin + creatin (Cr) while the ratio of Cholin/Cr was reduced. in urine spectroscopy the concentration of NAA was markedly increased. The ratio of NAA/creatin + creatinin was 880 +/- 10% mmol/mol (normal: 5-21 mmol/mol). Diagnosis of Canavan's disease was supported by gas chromatographic urine examination with an 80-100 fold elevation of NAA concentration. Hence, the diagnosis of Canavan's disease could be established by increased ratio of NAA/Cr and decreased ratio of Cho/Cr relation in brain spectroscopy and high NAA concentration in urine spectroscopy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7548871     DOI: 10.1055/s-2007-1015980

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  2 in total

1.  Decreasing choline signal--a marker of phenylketonuria?

Authors:  M Dezortová; L Hejcmanová; M Hájek
Journal:  MAGMA       Date:  1996 Sep-Dec       Impact factor: 2.310

2.  The human motor cortex after incomplete spinal cord injury: an investigation using proton magnetic resonance spectroscopy.

Authors:  B K Puri; H C Smith; I J Cox; J Sargentoni; G Savic; D W Maskill; H L Frankel; P H Ellaway; N J Davey
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.